Nightingale starts a new strategic partnership with 23andMe and launches a pilot
Translation: Original comment published in Finnish on 06/28/2024 at 6:23 pm EEST
The companies pilot Nightingale Health's Remote Health Check service with a group of 23andMe consumer members. If the pilot succeeds, we estimate that Nightingale’s service can be integrated into 23andMe’s subscription services. The partnership offers Nightingale a potential route to the US consumer market, to which it has not had a clear path so far. 23andMe is an internationally well-known player in genetic testing, and we believe that this partnership is another good sign of the attractiveness of Nightingale’s technology.
Serving consumers with a partnership model (B2B2C) has been one of the segments Nightingale has pursued in its strategy. Opening this segment in the US is, of course, another good sign of the company’s ability to implement its strategy. If successful, the partnership can also bring significant revenue growth to Nightingale. However, we do see direct healthcare customers (B2B/B2G) as more important for the company’s business growth. Nightingale has released a lot of positive news for the healthcare segment, most recently earlier on Friday.
Login required
This content is only available for logged in users
Nightingale Health
Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.
Read more on company pageKey Estimate Figures10.05.
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 4.2 | 4.7 | 8.7 |
growth-% | 80.80 % | 12.78 % | 85.00 % |
EBIT (adj.) | -18.5 | -17.8 | -17.6 |
EBIT-% (adj.) | -442.95 % | -377.50 % | -201.86 % |
EPS (adj.) | -0.30 | -0.27 | -0.27 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | 0.77 | - | - |